CCELHIGH SIGNALRISK10-K

CCEL faces a critical business disruption as Duke University terminated their key patent licensing agreement in May 2025, effectively blocking planned expansion into FDA-approved therapies for cerebral palsy and autism.

The Duke License Agreement termination represents a fundamental threat to CCEL's growth strategy, as the company has suspended investments in related activities and can no longer assure investors of its ability to expand into these therapeutic areas. The removal of multiple sclerosis from their target indications and the abandonment of their planned Cryo-Cell Institute for Cellular Therapies signals a significant strategic retreat.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

CCEL's financial position deteriorated substantially across most metrics, with operating income falling dramatically from $3.5M to $482K as the company pulled back on growth investments. Capital expenditures and share buybacks were both reduced by roughly 90%, while R&D spending declined meaningfully, reflecting the strategic pause following the Duke dispute. The company's cash position weakened to $319K from $561K, and stockholders' equity deficit expanded to -$18.6M, indicating mounting financial strain amid the licensing crisis.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-90.4%
$2.4M→$230K

Capex reduced 90.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Share Buybacks
Cash Flow
-88.1%
$1.4M→$170K

Buyback activity reduced 88.1% — capital being redeployed elsewhere or cash conservation underway.

Operating Income
P&L
-86.1%
$3.5M→$482K

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
-69.7%
$1.2M→$376K

R&D spending cut 69.7% — could signal cost discipline or concerning reduction in innovation investment.

Cash & Equivalents
Balance Sheet
-43.1%
$561K→$319K

Cash declined 43.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-40.8%
-$13.2M→-$18.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Inventory
Balance Sheet
-37.8%
$658K→$409K

Inventory drawn down 37.8% — strong sell-through or deliberate destocking; watch for supply constraints.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
As of February 28, 2026, there were 8,055,150 shares of Common Stock outstanding.
As discussed further in Note 18, on February 23, 2021, the Company entered into a Patent and Technology License Agreement (the Duke License Agreement ) with Duke University ( Duke ).
Food and Drug Administration ( FDA ) approved therapies, including cerebral palsy and autism.
As discussed further in Note 18, the Company has received from Duke a notice of termination of the License Agreement as of May 17, 2025.
As of the date hereof, it is unlikely that the Company will be able to expand its business into business units (2) and (3) above through the Duke License Agreement.
+7 more — sign up free →
REMOVED
As of February 28, 2025, there were 8,082,159 shares of Common Stock outstanding.
As discussed further in Note 12, effective as of February 23, 2021, the Company entered into a Patent and Technology License Agreement (the Duke License Agreement ) with Duke University ( Duke ).
Food and Drug Administration ( FDA ) approved therapies, including cerebral palsy, autism, and multiple sclerosis.
Additionally, to support such business expansion, the Company had anticipated opening and launching its Cryo-Cell Institute for Cellular Therapies, which it initially hoped to open as early as the fourth quarter of fiscal 2021, but no later than the first quarter of fiscal 2022, but more recently reported that it anticipated opening it during the fourth quarter of fiscal 2024.
As of the date hereof, the Company can make no assurances it will be able to expand its business into business units (2) and (3) above.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →